IN2013CH01199A - - Google Patents
Download PDFInfo
- Publication number
- IN2013CH01199A IN2013CH01199A IN1199CH2013A IN2013CH01199A IN 2013CH01199 A IN2013CH01199 A IN 2013CH01199A IN 1199CH2013 A IN1199CH2013 A IN 1199CH2013A IN 2013CH01199 A IN2013CH01199 A IN 2013CH01199A
- Authority
- IN
- India
- Prior art keywords
- formula
- compounds
- useful
- preparation
- pharmaceutically acceptable
- Prior art date
Links
- 108091005482 5-HT4 receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Priority Applications (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES13811624.9T ES2674993T3 (es) | 2013-03-20 | 2013-10-18 | Derivados de 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-HT4 |
| EA201591844A EA029365B1 (ru) | 2013-03-20 | 2013-10-18 | 5-амино-хинолин-8-карбоксамидные производные в качестве агонистов 5-htрецептора |
| JP2016504852A JP6185650B2 (ja) | 2013-03-20 | 2013-10-18 | ５−ｈｔ４受容体アゴニストとしての５−アミノ−キノリン−８−カルボキサミド誘導体 |
| BR112015024060A BR112015024060A2 (pt) | 2013-03-20 | 2013-10-18 | composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto |
| CA2907620A CA2907620C (en) | 2013-03-20 | 2013-10-18 | 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists |
| KR1020157030158A KR101815307B1 (ko) | 2013-03-20 | 2013-10-18 | 5-ht4 수용체 효능제로서 5-아미노-퀴놀린-8-카르복사미드 유도체 |
| IN1199CH2013 IN2013CH01199A (de) | 2013-03-20 | 2013-10-18 | |
| US14/777,925 US9790211B2 (en) | 2013-03-20 | 2013-10-18 | 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists |
| PCT/IN2013/000639 WO2014147636A1 (en) | 2013-03-20 | 2013-10-18 | 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists |
| DK13811624.9T DK2976337T3 (en) | 2013-03-20 | 2013-10-18 | 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists |
| MX2015012350A MX364929B (es) | 2013-03-20 | 2013-10-18 | Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4. |
| SG11201507763RA SG11201507763RA (en) | 2013-03-20 | 2013-10-18 | 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists |
| AU2013382944A AU2013382944B2 (en) | 2013-03-20 | 2013-10-18 | 5-Amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists |
| NZ712369A NZ712369A (en) | 2013-03-20 | 2013-10-18 | 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists |
| AP2015008742A AP2015008742A0 (en) | 2013-03-20 | 2013-10-18 | 5-amino quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists |
| EP13811624.9A EP2976337B1 (de) | 2013-03-20 | 2013-10-18 | 5-amino-chinolin-8-carboxamid- derivate als 5-ht4 rezeptor agonisten |
| CN201380074877.9A CN105164119B (zh) | 2013-03-20 | 2013-10-18 | 作为5‑ht4受体激动剂的5‑氨基‑喹啉‑8‑甲酰胺衍生物 |
| ZA2015/06804A ZA201506804B (en) | 2013-03-20 | 2015-09-14 | 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists |
| HK16105434.5A HK1217483A1 (zh) | 2013-03-20 | 2016-05-12 | 作爲 受體激動劑的 -氨基-喹啉- -甲酰胺衍生物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1199CH2013 IN2013CH01199A (de) | 2013-03-20 | 2013-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2013CH01199A true IN2013CH01199A (de) | 2015-08-14 |
Family
ID=54325095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1199CH2013 IN2013CH01199A (de) | 2013-03-20 | 2013-10-18 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9790211B2 (de) |
| EP (1) | EP2976337B1 (de) |
| JP (1) | JP6185650B2 (de) |
| KR (1) | KR101815307B1 (de) |
| CN (1) | CN105164119B (de) |
| AP (1) | AP2015008742A0 (de) |
| AU (1) | AU2013382944B2 (de) |
| BR (1) | BR112015024060A2 (de) |
| CA (1) | CA2907620C (de) |
| DK (1) | DK2976337T3 (de) |
| EA (1) | EA029365B1 (de) |
| ES (1) | ES2674993T3 (de) |
| HK (1) | HK1217483A1 (de) |
| IN (1) | IN2013CH01199A (de) |
| MX (1) | MX364929B (de) |
| NZ (1) | NZ712369A (de) |
| SG (1) | SG11201507763RA (de) |
| WO (1) | WO2014147636A1 (de) |
| ZA (1) | ZA201506804B (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201909997T4 (tr) * | 2015-02-13 | 2019-07-22 | Suven Life Sciences Ltd | 5-HT4 reseptör agonistleri olarak amid bileşikleri. |
| CN109444301A (zh) * | 2018-12-18 | 2019-03-08 | 江苏省中医院 | 一种测定血浆中普芦卡必利浓度的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5150393A (en) * | 1992-10-13 | 1994-05-09 | Smithkline Beecham Plc | Heterocyclic -esters or -amides used as 5-ht4 receptor antagonists |
| AU680453B2 (en) | 1992-11-05 | 1997-07-31 | Smithkline Beecham Plc | Piperidine derivatives as 5-HT4 receptor antagonists |
| FR2756564B1 (fr) * | 1996-12-04 | 2004-05-14 | Synthelabo | Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique |
| WO2001095902A1 (en) * | 2000-06-15 | 2001-12-20 | Respiratorius Ab | A composition comprising a combination of receptor agonists and antagonists |
| AU2004254193B2 (en) * | 2003-06-19 | 2010-02-18 | Janssen Pharmaceutica N.V. | 5ht4-antagonistic 4-(aminomethyl)-piperidine benzamides |
| ES2338882T3 (es) | 2003-11-24 | 2010-05-13 | Pfizer, Inc. | Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4. |
| EP1701951B1 (de) * | 2003-12-23 | 2010-02-10 | Serodus AS | Modulatoren von peripheren 5-ht-rezeptoren |
| WO2005092882A1 (en) * | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
| DK1856114T3 (en) | 2005-02-25 | 2014-11-17 | Raqualia Pharma Inc | Benzisoxazol-DERIVATIVES |
| US7906532B2 (en) | 2005-07-22 | 2011-03-15 | Pfizer Inc. | Indazole derivatives |
| GB0525661D0 (en) * | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Novel compounds |
| RU2569733C2 (ru) * | 2010-02-12 | 2015-11-27 | Раквалиа Фарма Инк. | Агонисты 5-нт4-рецепторов для лечения деменции |
| CN102762554A (zh) | 2010-02-16 | 2012-10-31 | 辉瑞大药厂 | 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇 |
-
2013
- 2013-10-18 IN IN1199CH2013 patent/IN2013CH01199A/en unknown
- 2013-10-18 AP AP2015008742A patent/AP2015008742A0/xx unknown
- 2013-10-18 NZ NZ712369A patent/NZ712369A/en not_active IP Right Cessation
- 2013-10-18 KR KR1020157030158A patent/KR101815307B1/ko active IP Right Grant
- 2013-10-18 CA CA2907620A patent/CA2907620C/en not_active Expired - Fee Related
- 2013-10-18 MX MX2015012350A patent/MX364929B/es active IP Right Grant
- 2013-10-18 CN CN201380074877.9A patent/CN105164119B/zh not_active Expired - Fee Related
- 2013-10-18 WO PCT/IN2013/000639 patent/WO2014147636A1/en active Application Filing
- 2013-10-18 SG SG11201507763RA patent/SG11201507763RA/en unknown
- 2013-10-18 DK DK13811624.9T patent/DK2976337T3/en active
- 2013-10-18 EP EP13811624.9A patent/EP2976337B1/de active Active
- 2013-10-18 ES ES13811624.9T patent/ES2674993T3/es active Active
- 2013-10-18 EA EA201591844A patent/EA029365B1/ru not_active IP Right Cessation
- 2013-10-18 BR BR112015024060A patent/BR112015024060A2/pt not_active IP Right Cessation
- 2013-10-18 AU AU2013382944A patent/AU2013382944B2/en not_active Ceased
- 2013-10-18 US US14/777,925 patent/US9790211B2/en not_active Expired - Fee Related
- 2013-10-18 JP JP2016504852A patent/JP6185650B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-14 ZA ZA2015/06804A patent/ZA201506804B/en unknown
-
2016
- 2016-05-12 HK HK16105434.5A patent/HK1217483A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ712369A (en) | 2016-11-25 |
| AP2015008742A0 (en) | 2015-09-30 |
| SG11201507763RA (en) | 2015-10-29 |
| KR20160004274A (ko) | 2016-01-12 |
| BR112015024060A2 (pt) | 2017-07-18 |
| ES2674993T3 (es) | 2018-07-05 |
| JP2016516089A (ja) | 2016-06-02 |
| US9790211B2 (en) | 2017-10-17 |
| EP2976337A1 (de) | 2016-01-27 |
| KR101815307B1 (ko) | 2018-01-04 |
| ZA201506804B (en) | 2016-07-27 |
| JP6185650B2 (ja) | 2017-08-23 |
| MX364929B (es) | 2019-05-14 |
| EP2976337B1 (de) | 2018-05-02 |
| CN105164119A (zh) | 2015-12-16 |
| CA2907620A1 (en) | 2014-09-25 |
| HK1217483A1 (zh) | 2017-01-13 |
| EA201591844A1 (ru) | 2016-08-31 |
| CN105164119B (zh) | 2017-12-08 |
| AU2013382944B2 (en) | 2016-08-04 |
| AU2013382944A1 (en) | 2015-10-08 |
| US20160280694A1 (en) | 2016-09-29 |
| CA2907620C (en) | 2018-03-13 |
| MX2015012350A (es) | 2016-05-09 |
| WO2014147636A1 (en) | 2014-09-25 |
| DK2976337T3 (en) | 2018-07-16 |
| EA029365B1 (ru) | 2018-03-30 |
| WO2014147636A8 (en) | 2014-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501321B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders | |
| PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
| IN2015DN01156A (de) | ||
| MX2016011632A (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| MD20150071A2 (ro) | Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni | |
| WO2014155300A3 (en) | Substitued pyrimidine amine derivatives as tak-1 inhibitors | |
| EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k | |
| TN2015000120A1 (en) | Oxazolidin-2-one-pyrimidine derivatives | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| MX2016005759A (es) | Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3). | |
| PH12017500089A1 (en) | Aldosterone synthase inhibitors | |
| EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
| MY176521A (en) | Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof | |
| MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
| IN2013MU03862A (de) | ||
| MX2016008898A (es) | Antagonistas selectivos de nr2b. | |
| MX2013013436A (es) | Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos. | |
| IN2013CH01199A (de) | ||
| EA201691252A1 (ru) | Соединения индазола в качестве агонистов 5-ht-рецептора | |
| MX2015000064A (es) | Compuestos de acrilamida como ligandos receptores de histamina h3. | |
| PH12015502703A1 (en) | Pharmaceutical compositions | |
| IN2013MU03838A (de) | ||
| MX2015012393A (es) | Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina. |